Status:

COMPLETED

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Brief Summary

This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the ...

Eligibility Criteria

Inclusion

  • All patients who are considered candidates to receive Herceptin for this indication

Exclusion

  • Patients for whom Herceptin is contraindicated

Key Trial Info

Start Date :

August 30 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 31 2016

Estimated Enrollment :

3942 Patients enrolled

Trial Details

Trial ID

NCT01152606

Start Date

August 30 2007

End Date

May 31 2016

Last Update

January 25 2018

Active Locations (205)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 52 (205 locations)

1

Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie

Graz, Austria, 8036

2

LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie

Graz, Austria, 8036

3

Lhk Klagenfurt; Abt. Für Gynäkologie

Klagenfurt, Austria, 9026

4

LKH Hochsteiermark; Abt. für Innere Medizin

Leoben, Austria, 8700